{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:33:58Z","timestamp":1786988038302,"version":"build-2736575974"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014812","name":"Nordic Pharma Group","doi-asserted-by":"publisher","award":["S-1"],"award-info":[{"award-number":["S-1"]}],"id":[{"id":"10.13039\/501100014812","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ejca.2026.116683","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:55:30Z","timestamp":1773968130000},"page":"116683","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Second-line liposomal irinotecan plus S-1 vs. liposomal irinotecan plus 5-fluorouracil in metastatic pancreatic cancer: The phase I\/II randomized NAPAN trial"],"prefix":"10.1016","volume":"239","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-6966-2356","authenticated-orcid":false,"given":"Anne M.","family":"Gehrels","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther N.","family":"Pijnappel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva H.","family":"van Daalen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0895-6387","authenticated-orcid":false,"given":"Simona","family":"Casalino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Zechetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2142-1352","authenticated-orcid":false,"given":"Alberto","family":"Quinzii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald W.","family":"Prager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2578-1766","authenticated-orcid":false,"given":"Judith","family":"de Vos-Geelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Macarulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4031-7585","authenticated-orcid":false,"given":"Davide","family":"Melisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0511-6323","authenticated-orcid":false,"given":"Mahsoem","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna W.","family":"Wilmink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejca.2026.116683_bib1","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"19","key":"10.1016\/j.ejca.2026.116683_bib2","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.ejca.2026.116683_bib3","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"issue":"10409","key":"10.1016\/j.ejca.2026.116683_bib4","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","article-title":"NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial","volume":"402","author":"Wainberg","year":"2023","journal-title":"Lancet"},{"issue":"10018","key":"10.1016\/j.ejca.2026.116683_bib5","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","article-title":"Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial","volume":"387","author":"Wang-Gillam","year":"2016","journal-title":"Lancet"},{"issue":"32","key":"10.1016\/j.ejca.2026.116683_bib6","doi-asserted-by":"crossref","first-page":"3914","DOI":"10.1200\/JCO.2016.68.5776","article-title":"PANCREOX: A Randomized Phase III Study of Fluorouracil\/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy","volume":"34","author":"Gill","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116683_bib7","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ejca.2017.05.025","article-title":"Second line with oxaliplatin- or irinotecan-based chemotherapy for gemcitabine-pretreated pancreatic cancer: a systematic review","volume":"81","author":"Petrelli","year":"2017","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2026.116683_bib8","doi-asserted-by":"crossref","first-page":"298","DOI":"10.5009\/gnl16307","article-title":"Efficacy of capecitabine plus oxaliplatin combination chemotherapy for advanced pancreatic cancer after failure of first-line gemcitabine-based therapy","volume":"11","author":"Chung","year":"2017","journal-title":"Gut Liver"},{"issue":"23","key":"10.1016\/j.ejca.2026.116683_bib9","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1200\/JCO.2013.53.6995","article-title":"Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial","volume":"32","author":"Oettle","year":"2014","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.ejca.2026.116683_bib10","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1200\/JCO.2012.43.3680","article-title":"Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study","volume":"31","author":"Ueno","year":"2013","journal-title":"J Clin Oncol"},{"issue":"10041","key":"10.1016\/j.ejca.2026.116683_bib11","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0140-6736(16)30583-9","article-title":"Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)","volume":"388","author":"Uesaka","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ejca.2026.116683_bib12","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00280-010-1311-3","article-title":"Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer","volume":"67","author":"Sudo","year":"2011","journal-title":"Cancer Chemother Pharm"},{"issue":"2","key":"10.1016\/j.ejca.2026.116683_bib13","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.116683_bib14","unstructured":"Common terminology criteria for adverse events (CTCAE) version 4.0 [PDF on the Internet]. 2001 [cited 2025 May 8]; Available from: \u3008https:\/\/www.eortc.be\/services\/doc\/ctc\/ctcae_4.03_2010-06-14_quickreference_5x7.pdf\u3009."},{"issue":"5","key":"10.1016\/j.ejca.2026.116683_bib15","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2026.116683_bib16","unstructured":"Guidance for industry. Patient-reported outcome measures: use in medical product development to support labelling claims [PFD on the internet]. 2009 [cited 2025 May 8]; Available from: \u3008https:\/\/www.fda.gov\/downloads\/drugs\/guidances\/ucm193282.pdf\u3009."},{"issue":"1","key":"10.1016\/j.ejca.2026.116683_bib17","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116683_bib18","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2025.4347","article-title":"CONSORT 2025 Statement: Updated Guideline for Reporting Randomized Trials","author":"Hopewell","year":"2025","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.ejca.2026.116683_bib19","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1001\/jama.2013.879","article-title":"Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension","volume":"309","author":"Calvert","year":"2013","journal-title":"Jama"},{"issue":"4","key":"10.1016\/j.ejca.2026.116683_bib20","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00280-007-0514-8","article-title":"A late phase II study of S-1 for metastatic pancreatic cancer","volume":"61","author":"Okusaka","year":"2008","journal-title":"Cancer Chemother Pharm"},{"key":"10.1016\/j.ejca.2026.116683_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115424","article-title":"Phase 1\/2 study of liposomal irinotecan plus S-1 for metastatic pancreatic cancer refractory to gemcitabine-based treatment","volume":"222","author":"Imaoka","year":"2025","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2026.116683_bib22","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s00535-024-02186-9","article-title":"Efficacy of liposomal irinotecan\u2009+\u20095-FU\/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probability of treatment weighting","volume":"60","author":"Imaoka","year":"2025","journal-title":"J Gastroenterol"},{"issue":"2","key":"10.1016\/j.ejca.2026.116683_bib23","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00280-008-0741-7","article-title":"A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer","volume":"63","author":"Morizane","year":"2009","journal-title":"Cancer Chemother Pharm"},{"issue":"4","key":"10.1016\/j.ejca.2026.116683_bib24","first-page":"257","article-title":"Comparison of the pharmacokinetics of S-1, an oral anticancer agent, in Western and Japanese patients","volume":"30","author":"Comets","year":"2003","journal-title":"J Pharm Pharm"},{"issue":"3","key":"10.1016\/j.ejca.2026.116683_bib25","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1007\/s10120-015-0587-8","article-title":"The efficacy and safety of S-1-based regimens in the first-line treatment of advanced gastric cancer: a systematic review and meta-analysis","volume":"19","author":"Ter Veer","year":"2016","journal-title":"Gastric Cancer"},{"issue":"8","key":"10.1016\/j.ejca.2026.116683_bib26","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s40265-013-0062-y","article-title":"S-1 (Teysuno\u00ae): A Review of Its Use in Advanced Gastric Cancer in Non-Asian Populations","volume":"73","author":"Sanford","year":"2013","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.ejca.2026.116683_bib27","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/cas.14264","article-title":"Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study","volume":"111","author":"Bang","year":"2020","journal-title":"Cancer Sci"},{"issue":"11","key":"10.1016\/j.ejca.2026.116683_bib28","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/S1470-2045(21)00486-1","article-title":"Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study","volume":"22","author":"Yoo","year":"2021","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2026.116683_bib29","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1093\/annonc\/mdx122","article-title":"Randomized phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer Group","volume":"28","author":"Kwakman","year":"2017","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2026.116683_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101199","article-title":"Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancer","volume":"8","author":"Punt","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2026.116683_bib31","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ejca.2018.09.029","article-title":"Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin","volume":"106","author":"Hubner","year":"2019","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2026.116683_bib32","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s12904-020-00610-4","article-title":"Quality of life of patients with metastatic pancreatic adenocarcinoma initiating first-line chemotherapy in routine practice","volume":"19","author":"Laquente","year":"2020","journal-title":"BMC Palliat Care"},{"key":"10.1016\/j.ejca.2026.116683_bib33","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.2147\/CMAR.S376261","article-title":"Health-related quality of life of patients with metastatic pancreatic cancer: a systematic literature review","volume":"14","author":"Yoo","year":"2022","journal-title":"Cancer Manag Res"},{"issue":"7","key":"10.1016\/j.ejca.2026.116683_bib34","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1158\/1078-0432.CCR-15-2035","article-title":"Focusing on core patient-reported outcomes in cancer clinical trials: symptomatic adverse events, physical function, and disease-related symptoms","volume":"22","author":"Kluetz","year":"2016","journal-title":"Clin Cancer Res"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926004636?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926004636?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T08:09:16Z","timestamp":1777622956000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926004636"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":34,"alternative-id":["S0959804926004636"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116683","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Second-line liposomal irinotecan plus S-1 vs. liposomal irinotecan plus 5-fluorouracil in metastatic pancreatic cancer: The phase I\/II randomized NAPAN trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116683","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116683"}}